ClinicalTrials.gg
CompletedNCT01599013JASINT1Updated Dec 8, 2015

JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin

A Phase 2 interventional study of Vinflunine, Gemcitabine and Vinflunine, Carboplatin in Bladder Transitional Cell Carcinoma Stage IV, sponsored by Pierre Fabre Medicament. Completed at 1 site in France. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2015-12-08.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing gemcitabine in Carcinoma, Transitional Cell — 3 open to participants now, 8 under way, 1 of them phase 3. Gemcitabine · Carcinoma, Transitional Cell.

Enrollment
10th of 27
69 · median 54
Started
2011
the only one that year
Phase 2
18 of 27
3 open now
Registered
11th of 27
by date

Among the 27 studies testing gemcitabine in Carcinoma, Transitional Cell, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 18 in phase 2, and was the 11th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

3 of the 27 studies testing gemcitabine in Carcinoma, Transitional Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing gemcitabine in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or metastatic urothelial carcinoma previously treated with a platinum-based regimen. The intent of this study is to clarify the benefit/risk ratio of the two most promising associations of cytotoxics including the novel therapeutic agent, vinflunine: vinflunine-gemcitabine and vinflunine-carboplatin.

Read the detailed description

Gemcitabine and carboplatin have been the most studied and used anticancer agents in cisplatin-unfit patients with advanced urothelial carcinoma. Both agents previously demonstrated clinical activity as single agent and/or as part of combination regimen in patients with advanced or metastatic disease even if clinical benefits and survival remains limited in this setting for this population.

The purpose of this study is to test in a randomized trial enrolling patients with renal impairment or moderate congestive heart failure two combinations of a novel cytotoxic agent, vinflunine, one with gemcitabine and another with carboplatin in order to determine the most promising combination in the first line treatment of advanced/metastatic urothelial carcinoma.

03

Conditions studied

  • Bladder Transitional Cell Carcinoma Stage IV

Keywords

  • urothelial carcinoma
  • bladder cancer
  • vinflunine
  • transitional cell carcinoma
  • advanced or metastatic
  • unfit
  • ineligible to cisplatin
  • renal impairment
  • renal insufficiency
  • urologic neoplasms
  • urogenital neoplasm
  • urinary neoplasms
  • cisplatin
  • tubulin inhibitors
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman aged ≥ 18 years and \< 80 years
  • Signed written
  • confirmed diagnosis of locally advanced or predominantly transitional cell carcinoma of the urothelium (TCCU)
  • Ineligibility for cisplatin-based therapy because of at least one of the following two medical conditions:

    • Calculated (Cockcroft-Gault formula)\< 60 mL/min
    • Classification Stage II-III Congestive Heart Failure (documented by medical history)
  • "Measurable" disease with at least one uni-dimensional lesion according to guideline (version 1.1)
  • performance status of 0 or 1
  • Estimated of at least 12 weeks
  • Patient without prior systemic anticancer therapy unless if it had been administered as or adjuvant chemotherapy (CT) for TCCU and if the patient has documented relapse ≥ 6 months after the last dose of CT (prior intravesical CT allowed)
  • Adequate bone marrow and hepatic functions as evidenced by:

    • ≥ 2,000/mm3 (≥ 2.0 x 109/L)
    • ≥ 10 g/dL
    • count ≥ 100,000/mm3
    • Serum total ≤ 1.5 x (ULN)
    • Transaminases ≤ 2.5 x ULN [≤ 5 x ULN only in case of liver metastasis]
  • Absence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions should be assessed with the patient before registration in the trial

Exclusion criteria

Exclusion Criteria:

  • performance status ≥ 2
  • Woman if pregnant or lactating or with positive pregnancy test at inclusion; woman of who did not use or is unwilling or unable to use an acceptable method to avoid pregnancy during the 2 months preceding the start of study treatment, for the entire study period and for up to 3 months after the last dose of study treatment; sexually active fertile man not using effective during the study and up to 6 months after the last dose of study treatment if his partner is a woman of child-bearing potential
  • Known or .
  • Peripheral neuropathy Grade ≥ 2 by NCI CTC
  • Prior radiation to ≥ 30% of the bone marrow or completed \< 30 days ago or without full recovery of toxicities
  • Other serious illness or medical condition including:

    • Infection requiring systemic anti-infective therapy
    • Any medical condition that might not be controlled, for instance patients with unstable angina, patients with myocardial infarction within 6 months or uncontrolled diabetes
  • Prior systemic chemotherapy for advanced or disease or /adjuvant chemotherapy that was completed \< 6 months before documented progression
  • Patient who had received any other drug or anti-cancer therapy within 30 days before randomisation
  • Other except adequately treated basal carcinoma of the skin, in-situ cervix carcinoma, localised prostate cancer with limited risk of recurrence (pT ≤ 2b, Gleason score ≤ 7) that was incidentally discovered and did not lead to any other treatment apart from prostatectomy, or any other tumor with a disease free interval ≥ 5 years
  • Inadequate renal function defined by a serum \< 30 mL/min (Cockcroft-Gault formula)
  • Known to the study drugs or to drugs with similar chemical structures
  • Patients who require treatment with ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, rifampicin (any potent inhibitor or inducer) or phenytoin
  • Any concurrent chronic system immune therapy or previous organ allograft
  • (ECG) with significant modifications suggesting a high risk of occurrence of an acute clinical event
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Other
    Vinflunine plus Gemcitabine

    Drug: Vinflunine, Gemcitabine

  • Other
    Vinflunine plus Carboplatin

    Drug: Vinflunine, Carboplatin

Interventions

  • DrugVinflunine, Gemcitabine

    Drug pages: Vinflunine · Gemcitabine

    * Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal * Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal

    Also known as: JAVLOR, GEMZAR

  • DrugVinflunine, Carboplatin

    Drug pages: Vinflunine · Carboplatin

    * Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal * Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal

    Also known as: JAVLOR, CBDCA

06

What researchers measure

Primary outcomes

  1. Disease control rate as defined by RECIST criteria (version 1.1) as a percentage of best overall responses of Complete (CR) + Partial (PR) + Stable Disease (SD) for both Vinflunine-Gemcitabine and Vinflunine-Carboplatin combinations

    Assessment of lesions (measurable and non-measurable) should be performed at baseline and every 6 weeks (assessment interval). Evaluable patients: all baseline lesions must have been assessed at least once after the second cycle (6 weeks); patients who progress before the first evaluation will be considered as early progression. Primary analysis is planned on the intent to treat population, secondary analysis being performed on the evaluable population.

    Time frame: Change from baseline in tumor assessment at 12 weeks (cycle 4)

Secondary outcomes

  1. Tumor Response Rate as defined by RECIST criteria (version 1.1) with a best response as Complete (CR) or Partial (PR)

    Assessment of lesions (measurable and non-measurable) should be performed at baseline and every 6 weeks (assessment interval). Evaluable patients: all baseline lesions must have been assessed at least once after the second cycle (6 weeks); patients who progress before the first evaluation will be considered as early progression.

    Time frame: Change from baseline in tumor assessment at 12 weeks (cycle 4)

  2. Duration of Disease control in Participants With Best Response of CR + PR + SD

    Tumor assessment at baseline and then every 6 weeks, until tumor progression. Duration of disease control according to investigator will be calculated among the responders and stable patients from the date of randomisation until the documentation of progression or death due to any cause. Patients who are lost to follow-up without progression, or reach the time point of analysis without a known record of progression or death will have the duration of disease control censored at the date of last tumour assessment or last contact of a follow-up showing no progression, whichever occur last.

    Time frame: From the date of randomisation until the date of documented progression or date of death due to any cause, assessed up to 10 months

  3. Duration of Response in Participants With Best Response of CR or PR

    Tumor assessment at baseline and then every 6 weeks, until tumor progression. Duration of response will be calculated among the responders (i.e. CR and PR) . Patients who are lost to follow-up, or reach the time point of analysis without a known record of progression or death will have the duration of response censored at the date of last tumour assessment or last contact of a follow-up showing no progression, whichever occur last.

    Time frame: From the date that measurement criteria are first met for complete or partial response until the date of documented progression or date of death due to any cause, assessed up to 10 months

  4. Time to First Response calculated among the responders

    Tumor assessment at baseline and then every 6 weeks. Will be calculated among the responders (i.e. CR and PR)

    Time frame: From the date of randomisation up to the first report of documented response, assessed up to 12 weeks (cycle 4).

  5. Time to Treatment Failure

    Tumor assessment (RECIST) every 6 weeks. Patients who reach the time point of analysis without failure as defined above will have the time to treatment failure censored at the date of last tumour assessment or last contact of a follow-up not showing progression. Patients who discontinued treatment for other reason and who are lost to follow-up will be censored at the date of last contact.

    Time frame: From the date of randomisation until tumor progression, unacceptable toxicity, withdrawal of patient consent, lost to follow-up or start of new anticancer therapy, assessed up to 10 months.

  6. Progression Free Survival

    Tumor assessment every 6 weeks (RECIST).Patients who are lost to follow-up, or reach the time point of analysis without a known record of progression or death will have the progression-free survival censored at the date of last tumour assessment or last contact of a follow-up showing no progression, whichever occur last.

    Time frame: From the date of randomisation until the date of progression or the date of death from any cause if no progression was recorded before, median patient follow-up of 11 months

  7. Overall Survival

    Data recording every 3 months. For patients who have not died, survival time will be censored at the date of last news (i.e: date of last administration, tumor assessment, clinical examination, haematological or biochemistrical assessment or date of last contact).

    Time frame: From the time of randomisation up to death or last follow-up, assessed with a median patient follow-up of 15 months (assessed up to 24 months)

  8. Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Discontinuation

    Population: all treated patients unless the patient is lost to follow-up immediately after the start of the treatment. The patients will be analysed in the treatment arm they actually received. The NCI-CTC classification version 2.0 will be used to classify toxicities. Maximum grade or severity will be reported by cycle and by patient for each MedDRA Preferred Term. Analyses will be performed both regardless the relationship to treatment and related to treatment. Biochemical toxicities: the worst CTCAE version 2.0 grade will be analysed according to the grade present at baseline.

    Time frame: AE and SAE will be collected up to 30 days after the last treatment administration, on an expected average period of 17 weeks

07

Study locations

1 site
  • Pierre Fabre Research Institute
    Boulogne, France
08

References and documents

Publications

  • De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissiere N, Culine S. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016 Mar;27(3):449-54. doi: 10.1093/annonc/mdv609. Epub 2015 Dec 16. PubMed 26673352 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Oct 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2012
First posted
May 15, 2012
Start
Feb 2011
Primary completionActual
Oct 2013
CompletionActual
Apr 2014
Last update
Dec 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01599013
Responsible party
Sponsor
First posted
May 15, 2012
Start date
Feb 2011
Primary completion
Oct 2013
Completion
Apr 2014
Last update
Dec 8, 2015

Study contacts

Maria De Santis, MD
principal investigator · Center for Oncology and Hematology Kaiser Franz Josef Hospital - Vienna - Austria
Stéphane Culine, MD
principal investigator · University Hospital St Louis - Paris - France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vinflunine · Gemcitabine · Carboplatin

Start the discussion